The results of evisceration with primary porous implant placement in patients with endophthalmitis.
OBJECTIVE
To assess the results and long-term prognosis of evisceration with primary porous implant placement in patients with endophthalmitis.


METHODS
A retrospective study was conducted to review the files of 27 patients (29 eyes) with endophthalmitis who underwent evisceration with primary porous implant placement from January 1997 to December 2007 at St. Mary's Hospital and Kangnam St. Mary's Hospital. The mean follow-up period was 12.24 months (range, 3 to 89 months) and the mean age of the patients was 63.6 years (range, 33 to 89 years).


RESULTS
During the surgical procedure, primary implant placement was successfully completed, and any postoperative infection or inflammation rapidly resolved in all 27 patients (29 eyes). One of two porous implant materials was used. Hydroxyapatite was inserted in 14 eyes and Medpor was inserted in 15 eyes. Delayed implant exposure was noted in 1 eye, which was treated by inserting a hydroxyapatite implant 18 months after the first surgery. This was well treated by a preserved scleral graft. Implant infection was noted in 1 other eye at 20 days after the first surgery. All other minor complications healed without sequelae.


CONCLUSIONS
Evisceration with primary porous implant placement as the treatment for recalcitrant endophthalmitis resulted in rapid resolution of any infection and inflammation. Implant exposure and infection occurred in only 2 eyes, and these problems were well treated without long-term sequelae. Therefore, evisceration with primary porous implant placement is a treatment option for patients with endophthalmitis.
Department of Ophthalmology and Visual Science, Seoul St. Mary's Hospital, The Catholic University of Korea School of Medicine, Seoul, Korea.
Young-Gun
YG
Park
Ji-Sun
JS
Paik
Suk-Woo
SW
Yang
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D009877:Endophthalmitis / Q000382:microbiology / Q000601:surgery*; D017234:Eye Evisceration; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D020273:Orbital Implants; D016062:Porosity; D011379:Prognosis; D012189:Retrospective Studies; D016896:Treatment Outcome